{"transactions":[{"id":739810,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-13T00:06:14.000Z","date":"2026-06-12","kind":"exercise","planned":true,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":519588,"derivative":{"exercise_price":1.5,"expiration_date":"2032-05-23","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001951287-26-000004","document":"form4-06132026_120610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000195128726000004/form4-06132026_120610.xml","form_type":"4"}},{"id":739809,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-06-13T00:06:14.000Z","date":"2026-06-12","kind":"sale","planned":true,"acquired":false,"shares":25000,"price":10,"value":250000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025."}],"balance_after":12176,"source":{"system":"sec-edgar","filing":"0001951287-26-000004","document":"form4-06132026_120610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000195128726000004/form4-06132026_120610.xml","form_type":"4"}},{"id":739808,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-06-13T00:06:14.000Z","date":"2026-06-12","kind":"exercise","planned":true,"acquired":true,"shares":25000,"price":1.5,"value":37500.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,861 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on December 31, 2025."}],"balance_after":37176,"source":{"system":"sec-edgar","filing":"0001951287-26-000004","document":"form4-06132026_120610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000195128726000004/form4-06132026_120610.xml","form_type":"4"}},{"id":951495,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-01-05T21:26:31.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026."}],"balance_after":240000,"derivative":{"exercise_price":11.49,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001951287-26-000002","document":"form4-01052026_090126.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000195128726000002/form4-01052026_090126.xml","form_type":"4"}},{"id":1092380,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-03T20:21:24.000Z","date":"2025-07-01","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Immediately exercisable."}],"balance_after":544588,"derivative":{"exercise_price":1.5,"expiration_date":"2032-05-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-25-019321","document":"form4-07032025_080720.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925019321/form4-07032025_080720.xml","form_type":"4"}},{"id":1092379,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-07-03T20:21:24.000Z","date":"2025-07-01","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":16.9907,"value":254860.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $16.9907, and the range of prices were between $16.71 and $17.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":10315,"source":{"system":"sec-edgar","filing":"0001415889-25-019321","document":"form4-07032025_080720.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925019321/form4-07032025_080720.xml","form_type":"4"}},{"id":1092378,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-07-03T20:21:24.000Z","date":"2025-07-01","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":1.5,"value":22500.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 2,619 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2025."}],"balance_after":25315,"source":{"system":"sec-edgar","filing":"0001415889-25-019321","document":"form4-07032025_080720.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925019321/form4-07032025_080720.xml","form_type":"4"}},{"id":1105016,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T22:38:45.000Z","date":"2025-06-18","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately exercisable."}],"balance_after":559588,"derivative":{"exercise_price":1.5,"expiration_date":"2032-05-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-25-017901","document":"form4-06202025_100641.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925017901/form4-06202025_100641.xml","form_type":"4"}},{"id":1105015,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-06-20T22:38:45.000Z","date":"2025-06-18","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":16,"value":240000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024."}],"balance_after":7696,"source":{"system":"sec-edgar","filing":"0001415889-25-017901","document":"form4-06202025_100641.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925017901/form4-06202025_100641.xml","form_type":"4"}},{"id":1105014,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-06-20T22:38:45.000Z","date":"2025-06-18","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":1.5,"value":22500.0,"ownership":{"direct":true},"balance_after":22696,"source":{"system":"sec-edgar","filing":"0001415889-25-017901","document":"form4-06202025_100641.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925017901/form4-06202025_100641.xml","form_type":"4"}},{"id":1194650,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-21T22:30:14.000Z","date":"2025-03-20","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":574588,"derivative":{"exercise_price":1.5,"expiration_date":"2032-05-23","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-25-008796","document":"form4-03212025_060301.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925008796/form4-03212025_060301.xml","form_type":"4"}},{"id":1194649,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-21T22:30:14.000Z","date":"2025-03-20","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":14,"value":140000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024."}],"balance_after":7696,"source":{"system":"sec-edgar","filing":"0001415889-25-008796","document":"form4-03212025_060301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925008796/form4-03212025_060301.xml","form_type":"4"}},{"id":1194648,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-21T22:30:14.000Z","date":"2025-03-20","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":1.5,"value":15000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 2,003 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on December 31, 2024."}],"balance_after":17696,"source":{"system":"sec-edgar","filing":"0001415889-25-008796","document":"form4-03212025_060301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925008796/form4-03212025_060301.xml","form_type":"4"}},{"id":1314772,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-01-03T21:30:31.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":152300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2025."}],"balance_after":152300,"derivative":{"exercise_price":10.71,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":152300},"source":{"system":"sec-edgar","filing":"0001415889-25-000459","document":"form4-01032025_040122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925000459/form4-01032025_040122.xml","form_type":"4"}},{"id":1342918,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-05T02:40:04.000Z","date":"2024-12-04","kind":"exercise","planned":true,"acquired":false,"shares":6283,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":584588,"derivative":{"exercise_price":1.5,"expiration_date":"2032-05-23","underlying":"Common Stock","underlying_shares":6283},"source":{"system":"sec-edgar","filing":"0001415889-24-028349","document":"form4-12042024_091201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924028349/form4-12042024_091201.xml","form_type":"4"}},{"id":1342917,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-05T02:40:04.000Z","date":"2024-12-02","kind":"exercise","planned":true,"acquired":false,"shares":3717,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":590871,"derivative":{"exercise_price":1.5,"expiration_date":"2032-05-23","underlying":"Common Stock","underlying_shares":3717},"source":{"system":"sec-edgar","filing":"0001415889-24-028349","document":"form4-12042024_091201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924028349/form4-12042024_091201.xml","form_type":"4"}},{"id":1342916,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-12-05T02:40:04.000Z","date":"2024-12-04","kind":"sale","planned":true,"acquired":false,"shares":6283,"price":14,"value":87962.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024."}],"balance_after":5693,"source":{"system":"sec-edgar","filing":"0001415889-24-028349","document":"form4-12042024_091201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924028349/form4-12042024_091201.xml","form_type":"4"}},{"id":1342915,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-12-05T02:40:04.000Z","date":"2024-12-04","kind":"exercise","planned":true,"acquired":true,"shares":6283,"price":1.5,"value":9424.5,"ownership":{"direct":true},"balance_after":11976,"source":{"system":"sec-edgar","filing":"0001415889-24-028349","document":"form4-12042024_091201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924028349/form4-12042024_091201.xml","form_type":"4"}},{"id":1342914,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-12-05T02:40:04.000Z","date":"2024-12-02","kind":"sale","planned":true,"acquired":false,"shares":3717,"price":14.1139,"value":52461.3663,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $14.1139, and the range of prices were between $14.00 and $14.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each\nseparate price will be provided."}],"balance_after":5693,"source":{"system":"sec-edgar","filing":"0001415889-24-028349","document":"form4-12042024_091201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924028349/form4-12042024_091201.xml","form_type":"4"}},{"id":1342913,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-12-05T02:40:04.000Z","date":"2024-12-02","kind":"exercise","planned":true,"acquired":true,"shares":3717,"price":1.5,"value":5575.5,"ownership":{"direct":true},"balance_after":9410,"source":{"system":"sec-edgar","filing":"0001415889-24-028349","document":"form4-12042024_091201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924028349/form4-12042024_091201.xml","form_type":"4"}},{"id":1402412,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-19T20:30:30.000Z","date":"2024-09-18","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately exercisable."}],"balance_after":594588,"derivative":{"exercise_price":1.5,"expiration_date":"2032-05-23","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-023712","document":"form4-09192024_080927.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924023712/form4-09192024_080927.xml","form_type":"4"}},{"id":1402411,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-09-19T20:30:30.000Z","date":"2024-09-18","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":14,"value":140000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024."}],"balance_after":5693,"source":{"system":"sec-edgar","filing":"0001415889-24-023712","document":"form4-09192024_080927.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924023712/form4-09192024_080927.xml","form_type":"4"}},{"id":1402410,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-09-19T20:30:30.000Z","date":"2024-09-18","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":1.5,"value":15000.0,"ownership":{"direct":true},"balance_after":15693,"source":{"system":"sec-edgar","filing":"0001415889-24-023712","document":"form4-09192024_080927.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924023712/form4-09192024_080927.xml","form_type":"4"}},{"id":1426543,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-21T22:51:06.000Z","date":"2024-08-19","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":604588,"derivative":{"exercise_price":1.5,"expiration_date":"2032-05-23","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-021885","document":"form4-08212024_100803.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924021885/form4-08212024_100803.xml","form_type":"4"}},{"id":1426542,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-08-21T22:51:06.000Z","date":"2024-08-19","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":14,"value":140000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024."}],"balance_after":5693,"source":{"system":"sec-edgar","filing":"0001415889-24-021885","document":"form4-08212024_100803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924021885/form4-08212024_100803.xml","form_type":"4"}},{"id":1426541,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-08-21T22:51:06.000Z","date":"2024-08-19","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":1.5,"value":15000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes  1,984 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan (\"ESPP\") on June 30, 2023,  1,232 shares acquired under the ESPP on December 29, 2023 and 2,477 shares acquired under the ESPP on June 28, 2024."}],"balance_after":15693,"source":{"system":"sec-edgar","filing":"0001415889-24-021885","document":"form4-08212024_100803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924021885/form4-08212024_100803.xml","form_type":"4"}},{"id":1687846,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock option (right to buy)","published_at":"2024-01-04T21:47:38.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option shall vest on January 1, 2025, and the remaining shares will vest monthly thereafter over three years."}],"balance_after":200000,"derivative":{"exercise_price":5.58,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001209191-24-000818","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919124000818/doc4.xml","form_type":"4"}},{"id":2062718,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock option (right to buy)","published_at":"2023-01-05T22:00:44.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on January 1, 2024, and the remaining shares will vest monthly thereafter over three years."}],"balance_after":50000,"derivative":{"exercise_price":8.42,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-23-001928","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919123001928/doc4.xml","form_type":"4"}},{"id":2120058,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock option (right to buy)","published_at":"2022-11-10T23:00:47.000Z","date":"2022-11-08","kind":"grant","acquired":true,"shares":614588,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for a stock option to acquire 520,000 shares of common stock of ARS Pharmaceuticals, Inc. (\"ARS\") with the exercise price of $1.77 per share pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\"), as amended (the \"Merger Agreement\"). Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the \"Merger\"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer.  Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date."}],"balance_after":614588,"derivative":{"exercise_price":1.5,"expiration_date":"2032-05-24","underlying":"Common Stock","underlying_shares":614588},"source":{"system":"sec-edgar","filing":"0001209191-22-056446","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919122056446/doc4.xml","form_type":"4"}}]}